- 询价
- 2026年05月27日
15 年金牌会员
企业认证
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 库存：
大量
- 年限：
TNM stage I, grade 3
- 组织来源：
duct
- 物种来源：
人
- 是否是肿瘤细胞：
1
- 运输方式：
冻存运输
- 相关疾病：
导管癌
- ATCC Number：
CRL-2324™
- 生长状态：
贴壁生长
- 细胞形态：
上皮样
- 器官来源：
乳房
| Designations: | HCC1395 | ||
| Depositors: | AF Gazdar, AK Virmani | ||
| Biosafety Level: | 1 | ||
| Shipped: | frozen | ||
| Medium & Serum: | See Propagation | ||
| Growth Properties: | adherent | ||
| Organism: | Homo sapiens | ||
| Morphology: | epithelial |
||
| Source: | Organ: mammary gland; breast Tissue: duct Tumor Stage: TNM stage I, grade 3 Disease: primary ductal carcinoma |
||
| Cellular Products: | Epithelial glycoprotein 2 (EGP2) cytokeratin 19 |
||
| Permits/Forms: | In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. | ||
| Restrictions: | The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. Adi F. Gazdar and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 648-1888, Email TechnologyDevelopment@UTSouthwestern.edu, or Fax: (214) 951-0935. | ||
| Isolation: | Isolation date: December 14, 1994 | ||
| Applications: | The cells are poorly differentiated and vacuolated. The cells are negative for expression of Her2-neu but positive for expression of p53. HCC1395 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 (EGP2) and for cytokeratin 19. The cells are negative for expression of estrogen receptors (ER -) according to depositor and negative for expression of progesterone receptors (PR -). |
||
| Receptors: | estrogen receptor, negative according to depositor progesterone receptor, negative |
||
| Oncogene: | her2/neu -, p53 + | ||
| DNA Profile (STR): | Amelogenin: X CSF1PO: 11 D13S317: 9 D16S539: 11 D5S818: 11 D7S820: 10,12 THO1: 9.3 TPOX: 11 vWA: 15 |
||
| Cytogenetic Analysis: | polyploid | ||
| Age: | 43 years adult | ||
| Gender: | female | ||
| Ethnicity: | Caucasian, White | ||
| Comments: | This cell line was initiated on 12/14/94 from a patient with a family history of cancer (patient's mother had breast cancer). The cell line took 14 months to establish. The tumor was classified as TNM stage I, grade 3, invasive ductal carcinoma with 0 out of 34 lymph node metastasis. The cells are poorly differentiated and vacuolated. The cells are negative for expression of Her2-neu but positive for expression of p53. HCC1395 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 (EGP2) and for cytokeratin 19. The cells are negative for expression of estrogen receptors (ER -) according to depositor and negative for expression of progesterone receptors (PR -). An EBV transformed lymphoblastoid cell line (HCC1395BL) from the same patient is available as ATCC CRL-2325 . |
||
| Propagation: | ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%. Temperature: 37.0°C Atmosphere: air, 95%; carbon dioxide (CO2), 5% |
||
| Subculturing: | Protocol: Remove medium, and rinse with 0.25% trypsin, 0.53 mM EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach. Add fresh culture medium, aspirate and dispense into new culture flasks. Subcultivation Ratio: A subcultivation ratio of 1:2 is recommended Medium Renewal: Every 2 to 3 days |
||
| Preservation: | Freeze medium: Complete growth medium 95%; DMSO, 5% Storage temperature: liquid nitrogen vapor phase |
||
| Related Products: | Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001 recommended serum:ATCC 30-2020 purified DNA:ATCC CRL-2324D normal (or near-normal) cell line established from the same patient:ATCC CRL-2325 purified RNA:ATCC CRL-2324R cell pellet:ATCC CRL-2324P |
||
| References: | 38266: Gazdar AF, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78: 766-774, 1998. PubMed: 9833771 | ||
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验相关实验
Direct DNA Injection (p53) into HCC Tumors
Liver tumors, specially HCC, are among the most common malignancies in the world, and their annual world incidence is about 250,000 cases, with a male to female ratio 4:1 (1 ). HCC is one of the most important neoplasms in tropical
文献速递：全面液体分析循环肿瘤DNA和蛋白质生物标志物为评估预后带来新的可能
研究背景 肝细胞癌（HCC）被认为是中国癌症相关死亡率的第三大原因。尽管手术是治疗HCC的较佳选择，但由于缺乏早期症状，大多数患者在癌症晚期才被诊断出来，因此肿瘤复发的风险很高。识别可能复发的患者并给予对应的辅助治疗，仍然是一个临床难题。循环肿瘤DNA（ctDNA），也可称为肿瘤衍生的细胞游离DNA，包含有关肿瘤基因组图谱的全面信息，包括单核苷酸变异（SNVs）、拷贝数变异（CNVs）和表观遗传变异。将ctDNA与HCC中的传统血清蛋白生物标志物结合将为无创监测实时肿瘤进展提供新的可能。
学问题。 案例一：多组学分析揭示肝癌起始细胞免疫逃逸机制和精准治疗策略 发表期刊：Cancer Cell 影响因子：44.5 发表时间：2024 年 12 月 研究疾病：肝细胞癌（Hepatocellular Carcinoma,HCC） 样本类型：患者来源的肝癌类器官（HCC organoids），肝癌细胞系（Hep3B,Huh7,PLC/PRF/5, MHCC97 H,Hep53.4）和小鼠模型（包括自发性肝癌模型和异种移植模型） 样本数量：11 个 HCC 类器官样本，4 个肝癌细胞系样本
技术资料暂无技术资料 索取技术资料
HCC1395
询价
